Nasdaq GlobeNewswire

Aurora Signs Collaboration Agreement with Major Research Institute

Del

Aurora Solar Technologies Inc. / Aurora Signs Collaboration Agreement with Major Research Institute . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

NORTH VANCOUVER, B.C., March 29, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora") ("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) is pleased to announce that it has entered into a Collaborative Research Agreement (CRA) with the Solar Energy Research Institute of Singapore (SERIS). SERIS is a top-tier applied research institute and has close ties with solar product manufacturers throughout Asia. The purpose of Aurora's joint research with SERIS is to advance the infrared reflection and transmission measurement techniques commercially pioneered in the DecimaTM family of products. The Company expects that this will lead to several new commercial applications for the Decima products in solar cell production and will also create opportunities in the growing R&D market for solar cell design and qualification. Under a separate purchase agreement, Aurora will supply SERIS with its latest Decima infrared measurement system, which will be used to characterize the advanced solar cells developed by SERIS. 

In January, the Company announced a cooperative project with SERIS on extending the Decima measurement capabilities to include heterojunction (HJ) solar cell manufacturing. HJ technology is a high-efficiency solar cell design that is rapidly being adopted in the industry.  This project is already bearing fruit with several solar cell manufacturers expressing interest in evaluating Aurora's HJ capabilities.  Now, with the signing of this CRA, Aurora is joining major cell manufacturers and production equipment makers who are working with SERIS to define and realize the next generation of solar cells, modules and manufacturing technologies as the industry continues growing at over 30 percent per year.

The CRA research is focused on a number of solar cell properties that are critical to quality and performance, such as emitter surface concentration and junction depth that cannot practically be measured in production. Even laboratory testing of these properties is time-consuming and expensive, and in some cases there is no practical way to directly measure the properties at all. However, both Aurora and SERIS anticipate that investigation and further refinement of IR characterization technology can lead to the means to rapidly and easily measure these properties in both volume production and laboratory applications. Realization of these capabilities can have the potential to allow solar cell manufacturers to more quickly and effectively qualify new cell designs, ramp up production lines and control variations in production.

"We have established a strong industry presence with a superior product and increasing orders. This important collaboration will now build on this by combining SERIS' research resources and broad industry contacts with our Decima IR technology base and commercial capabilities. This will enable us to expand our technology capabilities and customer base to meet the continuous demands for more efficient cell designs and process improvements in this explosive global industry," said Gordon Deans, Aurora's Chief Operating Officer.

"We are pleased to be increasing the depth and breadth of our relationship with Aurora," said Dr. Armin Aberle, SERIS' CEO. "In our work to advance the state of the art in the solar energy industry, SERIS works closely with numerous manufacturers and production equipment vendors. We expect that our work with Aurora will make a strong contribution to this industry development."

About Aurora Solar Technologies:

Aurora's mission is to deliver exceptional results to the photovoltaic industry through measurement, visualization and control of critical processes during solar cell manufacturing. We measure and map the results of critical cell fabrication processes, providing real-time visualization of material properties, cell parameters and production tool performance. Our products provide process engineers and production-line operators with the means to rapidly detect, analyze and correct process excursions, limit variations, and optimize processes, thereby increasing yield and profits. We are creating the quality control standard for the global photovoltaic manufacturing industry.  For more information, Aurora's website is located at www.aurorasolartech.com.

About the Solar Energy Research Institute of Singapore (SERIS):

The Solar Energy Research Institute of Singapore (SERIS) at the National University of Singapore (NUS) is Singapore's national institute for applied solar energy research. SERIS conducts research, development, testing and consulting on solar energy technologies and their integration into power systems and buildings. The Institute's R&D spectrum covers materials, components, processes, systems and services, with an emphasis on solar photovoltaic cells, modules and systems. SERIS' research team includes more than 200 scientists, engineers, technicians and Ph.D. students. SERIS collaborates closely with universities, research organizations, government agencies and industry. The collaborations with companies from the global solar sector span from small start-ups to industry leading heavyweights. For more information, SERIS' website is located at www.seris.sg.

For further information contact:

Michael Heaven, P.Eng., MBA
President & Chief Executive Officer
Aurora Solar Technologies Inc. 
Phone: +1 (778) 241-5000 
info@aurorasolartech.com

Investor Relations contact:
Nina Lafleur
Phone: +1 (604) 679-9964
info@aurorasolartech.com

Paradox Public Relations
Phone: +1 (514) 341-0408
info@paradox-pr.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward­ looking information. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. The Company does not assume the obligation to update any forward­ looking statement.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aurora Solar Technologies Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressemelding

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressemelding

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

SolarWinds Deepens Infrastructure Visibility with Log Manager for Orion17.7.2018 12:30Pressemelding

New log management solution delivers integrated, comprehensive event log management, collection, and consolidation to boost time-to-resolution AUSTIN, Texas, July 17, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today announced SolarWinds®Log Manager for Orion®, a new, powerful log management tool for on-premises IT environments. Fully integrated with the SolarWinds Orion Platform, Log Manager is designed to provide the essential components an IT operations team needs for improved log monitoring, troubleshooting, and performance management. While IT infrastructure generates vast amounts of log data each day-from syslogs to SNMP traps and Windows® events-the responsibility of evaluating the information to determine which is most valuable falls on the shoulders of technology professionals. Log Manager, the latest addition to the larger SolarWinds network and systems management portfolio, is designed to provide integrated log m

SD-WAN Market Leader Aryaka Further Expands within Canada to Help Global Enterprises to Accelerate Digital Transformation Strategies17.7.2018 11:19Pressemelding

SAN MATEO, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today it has further expanded its worldwide network with the addition of a new Point of Presence (POP) in Toronto, Canada. This investment was spurred by a rapidly growing presence of global enterprises with sites in Canada who, as part of their digital transformation initiatives, are looking for better application performance, multi-cloud connectivity, and security from their network. With the deployment of its POP in Canada, Aryaka extends its SD-WAN as-a-Service into this region and can now offer it directly to Canadian enterprises. As over 70% of Aryaka's business comes through channel partners, this expansion will further enable their success in meeting the connectivity, application performance, and digital transformation needs of their global enterprise customers. "We are thrilled to further expand our network and market footprint in Canada and improve the performance of Ar

Two London ex-Bankers launch first UK regulated Digital Asset Trading Platform and Crypto exchange accessible to Institutional Investors16.7.2018 17:37Pressemelding

LONDON, July 16, 2018 (GLOBE NEWSWIRE) -- UK's first native crypto exchange platform is on its way to become a reality. Sovren Exchange, a venture founded by a team of London-based banking executives, has announced an Initial Coin Offering (ICO) to begin Q3 of this year. For their launch, Sovren (SVRN) is raising a maximum of 10 Million USD (combination of Equity Funding and its own Sovren Token) to create a hybrid order book and brokerage exchange platform that uses a trading engine supported by Artificial Intelligence (AI) and Robotic Process Automation (RPA). Sovren will have a fully compliant platform that will support trading in derivates, equities, commodities and securities. The platform will use intelligent automation to address liquidity challenges and a 3rd party custodial service for additional protection with a European Bank. Sovren is supporting trading between all major crypto assets and fiat currencies like pounds, euros, and dollars, aiming for same day service and low,

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom